Molecular testing for respiratory pathogens helps laboratories maximize sensitivity for common viruses, including SARS-CoV-2, influenza, and RSV. Adoption of multiplex testing assays has grown over the last few years, most notably as a response to the SARS-CoV-2 pandemic. Although we have entered an endemic phase, we expect SARS-CoV-2 and its variants to remain with us indefinitely. SARS-CoV-2 now joins the list of respiratory pathogens that pathologists will see in the lab, and influenza and COVID-19 share symptoms, making differential detection even more challenging.
Multiplex testing assays allow laboratories to test for multiple infectious disease targets in a single reaction. This helps providers rule out multiple respiratory infections with one patient sample.
For Research Use Only. Not for use in diagnostic procedures.